Receptor-mediated Toxicity of Human Amylin Fragment Aggregated by Short- and Long-term Incubations with Copper Ions
Overview
Authors
Affiliations
Human amylin (hA1-37) is a polypeptide hormone secreted in conjunction with insulin from the pancreatic β-cells involved in the pathogenesis of type 2 diabetes mellitus (T2DM). The shorter fragment hA17-29 than full-length peptide is capable to form amyloids "in vitro". Here, we monitored the time course of hA17-29 β-amyloid fibril and oligomer formation [without and with copper(II)], cellular toxicity of different amyloid aggregates, and involvement of specific receptors (receptor for advanced glycation end-products, RAGE; low-affinity nerve growth factor receptor, p75-NGFR) in aggregate toxicity. Fibril and oligomer formation of hA17-29 incubated at 37 °C for 0, 48, and 120 h, without or with copper(II), were measured by the thioflavin T fluorescence assay and ELISA, respectively. Toxicity of hA17-29 aggregates and effects of anti-RAGE and anti-p75-NGFR antibodies were evaluated on neuroblastoma SH-SY5Y viability. Fluorescence assay of hA17-29 indicates an initial slow rate of soluble fibril formation (48 h), followed by a slower rate of insoluble aggregate formation (120 h). The highest quantity of oligomers was recorded when hA17-29 was pre-aggregated for 48 h in the presence of copper(II) showing also the maximal cell toxicity (-44% of cell viability, p < 0.01 compared to controls). Anti-RAGE or anti-p75-NGFR antibodies almost abolished cell toxicity of hA17-29 aggregates. These results indicate that copper(II) influences the aggregation process and hA17-29 toxicities are especially attributable to oligomeric aggregates. hA17-29 aggregate toxicity seems to be mediated by RAGE and p75-NGFR receptors which might be potential targets for new drugs in T2DM treatment.
The therapeutic potential of carnosine: Focus on cellular and molecular mechanisms.
Caruso G, Di Pietro L, Cardaci V, Maugeri S, Caraci F Curr Res Pharmacol Drug Discov. 2023; 4:100153.
PMID: 37441273 PMC: 10333684. DOI: 10.1016/j.crphar.2023.100153.
Caruso G, Fresta C, Fidilio A, Lazzara F, Musso N, Cardaci V Molecules. 2023; 28(8).
PMID: 37110558 PMC: 10146178. DOI: 10.3390/molecules28083324.
Characterization of Carnosine Effect on Human Microglial Cells under Basal Conditions.
Caruso G, Privitera A, Saab M, Musso N, Maugeri S, Fidilio A Biomedicines. 2023; 11(2).
PMID: 36831010 PMC: 9953171. DOI: 10.3390/biomedicines11020474.
Caruso G Molecules. 2022; 27(10).
PMID: 35630780 PMC: 9143376. DOI: 10.3390/molecules27103303.
Awan Z, Alghamdi S, Alhakamy N, Okbazghi S, Alfaleh M, Badr-Eldin S Drug Deliv. 2022; 29(1):1536-1548.
PMID: 35612292 PMC: 9154778. DOI: 10.1080/10717544.2022.2072412.